Skip to main content

For US Healthcare Professionals Only

Quick Links

Prescribing information
REMS
- FINTEPLA® (fenfluramine)
- ZILBRYSQ® (zilucoplan)
Adverse Event Reporting
- Report an Adverse Event or Product Complaint
- Email
- 1-844-599-CARE (2273)
Connect With an MSL
Connect With Us

Main navigation

Home
Our Science
Scientific Education
Congress Materials
Publications
Medical Information
- Overview
- Submit Medical Inquiry
HCP Resources
Prescribing Information
Connect With an MSL
Connect With Us
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI® (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
REMS
FINTEPLA® (fenfluramine)
ZILBRYSQ® (zilucoplan)

Home HCP Resources

Slide Library

See HCP Resources

Slide Library

SORT BY:

Select product(s):

BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI® (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
None

Select topic(s):

Dermatology
- Hidradenitis Suppurativa
- Plaque Psoriasis
Epilepsy
- CDKL5 Deficiency Disorder
- Dravet Syndrome
- Focal Onset Seizures
- Lennox-Gastaut Syndrome
- Seizure Emergencies
Gastroenterology
- Crohn's Disease
- Women's Health
Rare Disease
- Generalized Myasthenia Gravis
- Thymidine Kinase 2 Deficiency
Rheumatology
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Women’s Health

Sort by

Order

*Includes seizure clusters and acute or prolonged seizures

5 result(s)

Bimekizumab in Axial Spondyloarthritis (AxSpA)

Bimekizumab in Psoriatic Arthritis (PsA)

EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2023 Update

Rethinking Seizure Emergencies

The IL-17 Story: All in the Family

Footer Left

UCB-Cares.com
UCB-USA.com
UCB.com

BIMZELX®, BRIVIACT®, CIMZIA®, FINTEPLA®, KYGEVVI®, NAYZILAM®, RYSTIGGO®, ZILBRYSQ®, UCBCares®, and UCBCOMPASS® are registered trademarks of the UCB Group of Companies. All other trademarks are the property of their respective holders.

©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved. All data collected on this site is governed by UCB’s Privacy Policy, Cookies Policy, as well as the site Terms and Conditions. This site is intended for US Healthcare Professionals only.

US-OT-2600001 February 2026

Sticky notice

Announcements

RHEUMATOLOGY

The Women's Health Fellowship Program application is now open. Learn More

UCB Medical is now on LinkedIn. Follow us

You are now leaving UCBCOMPASS^®

UCBCOMPASS^® offers links to third-party websites provided solely for your convenience that may assist you in locating other useful information. UCB is not responsible for content or privacy policies on linked third-party websites that are not under the control of UCB. Do you wish to continue?

Cancel Yes, Continue

This site is intended for Healthcare Professionals licensed in the United States.

UCBCOMPASS^® provides accurate, unbiased, and non-promotional scientific education and medical information on UCB products and disease areas of focus. This content is for informational purposes only and is not intended as medical advice. It may include information about products or uses that have not been approved by the U.S. Food and Drug Administration.

Notice about cookies
This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy.

By clicking “Confirm” I certify that I am a U.S. Healthcare Professional and have read and consent to this site’s use of cookies.

I am a patient or caregiver I am a non-U.S. Healthcare Professional

Footer Right

contactAll
Home
Contact Us
Site Map
LinkedIn

TOP